A research team, affiliated with UNIST has unveiled a key factor involved in the DNA damage response, homologous recombination (HR) and DNA interstrand crosslink (ICL) repair.
According to the research team, their findings are expected to establish an effective control environment for chromosome instability, a major factor in cancer evolution, and further help combat malignant tumours.
Published in the January 2023 issue of Nucleic Acids Research, this breakthrough has been jointly led by Professor Hongtae Kim and Professor Kyungjae Myung in the Department of Biological Sciences at UNIST, in collaboration with Professor Yonghwan Kim and his research team from Sookmyung Women’s University.
In this study, the research team demonstrated that, as a novel interaction partner of TRAIP, ZNF212 plays important roles in DNA damage signalling and HR for cell survival and genome maintenance, and likely act upstream of both NEIL3 and FA pathways for ICL repair.
They, then, further identified that TRAIP appears to function as important factor for ICL repair as a regulatory factor upstream of both the NEIL3 and FA pathways in mESC lines.
Their findings also revealed that TRAIP functions in ICL repair, as a master regulator.
“Our findings together with mESC lines used in this study will be informative to understand molecular basis of the ICL repair pathways in detail,” noted the research team.
The findings have been published in the online version of Nucleic Acids Research, an internationally renowned journal in the fields of biochemistry and molecular biology.
Article: ZNF212 promotes genomic integrity through direct interaction with TRAIP
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.